--- canonical_url: https://www.stockexpertai.com/earnings/cor last_updated: 2026-05-05T20:48:21.253Z --- # Cencora, Inc. (COR) Q4 FY2026 Earnings Preview > **[stale-preview-note]** Note: this preview was published before the 2026-05-06 earnings report. Results have since been released — verify against the latest filings. > This content was automatically generated with FMP live data + Q1 FY2026 earnings call transcript. Generated: 2026-05-05T20:48:20.947Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $305.90 (▲ 0.74%) | fmp:quote | | Market Cap | $59.5B | fmp:profile | | 52w range | $271.00 – $377.54 | fmp:quote | | Earnings | Wed 6 May | fmp:earnings-history | | EPS estimate | $4.80 (+9% YoY) | fmp:earnings-estimate | | Revenue estimate | $81.1B | fmp:earnings-estimate | | Beat streak | 8/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $415 (+35.7% upside) | fmp:price-target-consensus | | MoonshotScore | 36/100 | derived | | Council | 4/6 bullish | derived | | Munger verdict | Undervalued | derived | ## Cencora, Inc. — Q4 FY2026 Expectations Q4 consensus: revenue $81.1B^{[FMP est]}, EPS $4.80^{[FMP est]}. 8 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** BUY · **Council:** 4/6 · **Moonshot:** 36 = MoonshotScore 36^{[9-pillar formula]} + Council 4/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (5 metrics) ### 1. Fy26 Operating Income Guidance Cencora is raising its fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%, driven by the contribution from OneOncology. > "To reflect our performance and the contribution from our recently completed acquisition of OneOncology, we are raising our fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%." > — Robert Mauch, President and CEO, Expectation / Guide · Q1 FY2026 ### 2. Us Healthcare Solutions Growth The US healthcare solutions segment operating income growth expectation is increased to a range of 14% to 16% due to the strong performance and the acquisition of OneOncology. > "This is primarily driven by our increased growth expectations for the US healthcare solutions segment, where we now expect operating income growth to be in the range of 14% to 16% due to our acquisition of OneOncology and the continued strong execution and performance of the segment." > — James Cleary, Executive Vice President and CFO, Investor Focus · Q1 FY2026 ### 3. Us Healthcare Solutions Revenue US healthcare solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP-1s, and in specialty sales to health systems and physicians. > "US healthcare solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP-1s, and in specialty sales to health systems and physicians." > — James Cleary, Executive Vice President and CFO, Investor Focus · Q1 FY2026 ### 4. Glp 1 Sales Growth In the quarter, we continued to see strong sales growth in the US for GLP-1 products, which increased by $1 billion or 11% over the prior year quarter. > "In the quarter, we continued to see strong sales growth in the US for GLP-1 products, which increased by $1 billion or 11% over the prior year quarter." > — James Cleary, Executive Vice President and CFO, Investor Focus · Q1 FY2026 ### 5. International Healthcare Solutions Outlook In the International Healthcare Solutions segment, revenue growth is now expected to be in the range of 7% to 9% on an as-reported basis to reflect the weakening of the US dollar against many currencies. > "In the International Healthcare Solutions segment, we now expect revenue growth to be in the range of 7% to 9% on an as-reported basis to reflect the weakening of the US dollar against many currencies." > — James Cleary, Executive Vice President and CFO, Expectation / Guide · Q1 FY2026 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 7.0 | strong | Q1 vs Q2: healthy growth (+13.9%) | | Gross Margin | 0.0 | weak | Q1: low margin (3.3%, capital-intensive or commodity) | | Operating Leverage | 0.0 | weak | op margin weak (1.2%, under pressure) | | Cash Runway | 3.0 | weak | FCF negative ($-2.4B, external financing needed) | | R&D Intensity | 3.0 | weak | low R&D investment (0.0%, weak innovation) | | Price Momentum | 4.0 | medium | RSI 37.4 weak momentum, 50d below | | News Sentiment | 8.0 | strong | strong buy consensus (79%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +35.7% | | Ken Griffin | bear | flow · 50d MA below | | Jim Simons | neutral | quant · RSI 37 | | Klarman | bull | value · target upside +35.7% | | Buffett | bull | quality · ROE score 5/5 | | Munger | bull | valuation · target upside +35.7% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Undervalued - **Financial Health:** Moderate - **Margin of Safety:** Strong - **Interest Coverage:** Adequate - **ROIC vs WACC:** Healthy **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 37.4 — momentum zayıf — oversold yakınında değil ama alıcı baskısı az - **50d MA:** $331 — hisse %7.5 altında — kısa vadeli direnç - **200d MA:** $328 — hisse %6.8 altında — uzun vadeli baskı - **Volume (10d):** -42% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q2 FY25 | $4.42 | $4.11 | BEAT | -6.8% | | Q3 FY25 | $4.00 | $3.85 | BEAT | -1.9% | | Q4 FY25 | $3.84 | $3.79 | BEAT | +1.8% | | Q1 FY26 | $4.08 | $4.05 | +0.7% EPS | +6.7% | Q1 (February 4, 2026): EPS $4.08 vs $4.05 est^[FMP], +0.7% beat. D+1 movement: +6.7%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q4 EPS > $4.80 + CapEx discipline** Threshold: EPS > $4.80^{[FMP est]}. Target: Break above median target $415^{[FMP target]}; high target $440^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $4.80 + CapEx < $119.4M** Threshold: EPS ≈ $4.80^{[FMP est]}, Q4 CapEx < $119.4M^[FMP]. Target: Consolidation in the band between current $306^[FMP] and median $415^[FMP]. ### Scenario C · Miss **EPS < $4.66 or CapEx ≥ $119.4M** Threshold: EPS < $4.66^{[FMP est×0.97]}. Target: Current $306 below SMA200 $328^[FMP], if rejection continues, $279^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q1: EPS $4.08 vs $4.05 beat^[FMP], stock +6.7% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q1 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q1 FY26 ### CapEx shock Q1 CapEx $119.4M^{[FMP cashflow]}. Q1 op margin 1.2%^{[FMP op margin]} — this level in Q4 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $415 (+35.7% upside vs current $306) - **High / Low:** $440 / $360 - **Buy / Hold / Sell:** 11 / 3 / 0 - **Analyst count:** 4 (last quarter), 43 all-time ## Additional Transcript Insights ### 1. fy26_operating_income_guidance **Claim:** Cencora is raising its fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%, driven by the contribution from OneOncology. **Evidence (transcript):** "To reflect our performance and the contribution from our recently completed acquisition of OneOncology, we are raising our fiscal 2026 guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%." **Numbers:** 11.5%, 13.5%, 2026 ### 2. oneoncology_acquisition_impact **Claim:** The OneOncology acquisition is expected to be neutral, net of financing costs, to adjusted diluted EPS in its first twelve months. **Evidence (transcript):** "As a reminder, we expect OneOncology to be neutral, net of financing costs, to adjusted diluted EPS in its first twelve months." **Numbers:** — ### 3. us_healthcare_solutions_growth **Claim:** The US healthcare solutions segment operating income growth expectation is increased to a range of 14% to 16% due to the strong performance and the acquisition of OneOncology. **Evidence (transcript):** "This is primarily driven by our increased growth expectations for the US healthcare solutions segment, where we now expect operating income growth to be in the range of 14% to 16% due to our acquisition of OneOncology and the continued strong execution and performance of the segment." **Numbers:** 14%, 16% ### 4. international_healthcare_solutions_outlook **Claim:** In the International Healthcare Solutions segment, revenue growth is now expected to be in the range of 7% to 9% on an as-reported basis to reflect the weakening of the US dollar against many currencies. **Evidence (transcript):** "In the International Healthcare Solutions segment, we now expect revenue growth to be in the range of 7% to 9% on an as-reported basis to reflect the weakening of the US dollar against many currencies." **Numbers:** 7%, 9% ### 5. us_healthcare_solutions_revenue **Claim:** US healthcare solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP-1s, and in specialty sales to health systems and physicians. **Evidence (transcript):** "US healthcare solutions revenue was $76.2 billion, up 5% as we continue to see good volumes and revenue growth across our customer segments, including growth in GLP-1s, and in specialty sales to health systems and physicians." **Numbers:** 76.2, 5% ### 6. glp_1_sales_growth **Claim:** In the quarter, we continued to see strong sales growth in the US for GLP-1 products, which increased by $1 billion or 11% over the prior year quarter. **Evidence (transcript):** "In the quarter, we continued to see strong sales growth in the US for GLP-1 products, which increased by $1 billion or 11% over the prior year quarter." **Numbers:** $1 billion, 11% --- *Data source: FMP (live query, 2026-05-05), Q1 FY2026 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*